Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours

In total, ~85% of malignant gastrointestinal stromal tumours (GISTs) harbour activating mutations in one of the genes KIT or PDGFRA, while 10-15% of all GISTs have no detectable KIT or PDGFRA mutations, but could have alterations in genes of the succinate dehydrogenase complex or in BRAF, PIK3CA or...

Descripción completa

Detalles Bibliográficos
Autores principales: Bombac, Alenka, Zakotnik, Branko, Bucic, Marina, Dragos, Vita Setrajcic, Gazic, Barbara, Stegel, Vida, Klancar, Gasper, Novakovic, Srdjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170035/
https://www.ncbi.nlm.nih.gov/pubmed/32236636
http://dx.doi.org/10.3892/ijo.2020.5028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170035/
https://www.ncbi.nlm.nih.gov/pubmed/32236636
http://dx.doi.org/10.3892/ijo.2020.5028

Ejemplares similares